



## Dicot's nomination committee proposes Jan-Eric Österlund as new board member

**Press release: Uppsala, Sweden, April 4, 2023. The Nomination Committee of Dicot AB proposes that Jan-Eric Österlund be elected as a new member of the Board of Directors at the Annual General Meeting on May 23.**

The Nomination Committee, consisting of Dicot's three largest shareholders in terms of votes Bertil Lindkvist, Tore Robertsson and Arne Paalberg and with Chairman of the Board Eva Sjökvist Saers as convener, proposes Jan-Eric Österlund as a new member of Dicot's Board of Directors. The current board is thus strengthened with expertise in financing and establishing partnerships and business relationships.

The Nomination Committee also proposes the re-election of Eva Sjökvist Saers, Fredrik Buch, Mikael von Euler, Per-Göran Gillberg and Michael Zell. Lena Söderström has informed the Nomination Committee that she declines re-election. Eva Sjökvist Saers is proposed as Chairman of the Board.

Jan-Eric Österlund has a degree of Master of Science in Engineering from Chalmers University of Technology and a bachelor's degree with a focus on business administration from Uppsala University. He has worked as a researcher and teacher at the Stockholm School of Economics where he also was acting professor in business administration.

Jan-Eric has a broad industrial experience and has been executive vice President of Statskonsult and of Atomenergi and CEO of Masonite. In 1983 Jan-Eric formed a private equity group in London and was a board member of Ermitage Ltd. He organized the buyout of HemoCue from Pharmacia and was its chairman until it was sold.

Jan-Eric has been chairman or director of several public companies on stock exchanges in the US, Sweden, Switzerland, and Canada in finance, medtech, biotech, engineering, and paper industries, including Investment AB Skrinet, MVI Equity AB and Isofol Medical.

### **For further information, please contact:**

Eva Sjökvist Saers, Chairman of the Board

Phone: +46 705 50 73 71

E-mail: [Eva.Sjokvist.Saers@dicot.se](mailto:Eva.Sjokvist.Saers@dicot.se)

### **About Dicot AB**

Dicot is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to current available drugs. Today, over 500 million men suffer from these sexual dysfunctions and the market is valued at USD 7 billion. Dicot's strategy is to develop LIB-01 under own auspices until phase 2a studies and thereafter in partnership with larger, established pharmaceutical companies, finance and develop LIB-01 further to a registered pharmaceutical on the world market.

Dicot is listed on Spotlight Stock Market and has approximately 4,000 shareholders. For more information, please visit [www.dicot.se](http://www.dicot.se).